Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Acromegaly is a chronic systemic disease with many complications and is associated with
increased mortality when not adequately treated. Substantial advances in acromegaly …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Pituitary tumors account for about 15% of primary intracranial neoplasms. Proliferation of
pituitary cells, which secrete hormones, may result in a spectrum of endocrine symptoms …

Abstract In March 2011, the Acromegaly Consensus Group met to revise and update the
guidelines on the diagnosis and treatment of acromegaly complications. The meeting was …

AACE= American Association of Clinical Endocrinologists; BEL=“best evidence” level;
BMD= bone mineral density; CPAP= continuous positive airway pressure; CPG= clinical …

Context: Several studies have assessed mortality risk in patients treated for acromegaly. All
studies found a mortality that was higher than expected for the general population, but most …

Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …

Purpose Pituitary adenomas give rise to physical and psychological symptoms, which may
persist after biochemical cure. Growing attention has been paid to quality of life (QoL) in …